

GPR89 Antibody (monoclonal) (M01)

Mouse monoclonal antibody raised against a partial recombinant GPR89.

Catalog # AT2251a

Product Information

Application	E
Primary Accession	B7ZAQ6
Other Accession	BC003187
Reactivity	Human
Host	mouse
Clonality	monoclonal
Isotype	IgG2b Kappa
Clone Names	4D8
Calculated MW	52917

Additional Information

Gene ID	51463;653519
Other Names	Golgi pH regulator A, Protein GPR89A, Putative MAPK-activating protein PM01, Putative NF-kappa-B-activating protein 90, GPR89A, GPHRA, GPR89, SH120
Target/Specificity	GPR89 (AAH03187, 175 a.a. ~ 284 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Dilution	E~~N/A
Format	Clear, colorless solution in phosphate buffered saline, pH 7.2 .
Storage	Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.
Precautions	GPR89 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.

Background


GPR89A is a nearly identical copy of the GPR89B gene (MIM 612806).

References

The DNA sequence and biological annotation of human chromosome 1. Gregory SG, et al. Nature, 2006 May 18. PMID 16710414. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Gerhard DS, et al. Genome Res, 2004 Oct. PMID 15489334. Complete sequencing and characterization of 21,243 full-length human cDNAs. Ota T, et al. Nat Genet, 2004 Jan. PMID 14702039. The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and

transmembrane proteins: a bioinformatics assessment. Clark HF, et al. Genome Res, 2003 Oct. PMID 12975309. Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways. Matsuda A, et al. Oncogene, 2003 May 22. PMID 12761501.

Images



Detection limit for recombinant GST tagged GPR89 is approximately 1 ng/ml as a capture antibody.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.